RT Journal Article
SR Electronic
T1 Acute nasal dryness in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.18.20233874
DO 10.1101/2020.11.18.20233874
A1 Jordi Navarra
A1 Alba Ruiz-Ceamanos
A1 Juan José Moreno
A1 José María García-Basterrechea
A1 Josep de Haro-Licer
A1 Scott Sinnett
A1 Charles Spence
A1 David Gallardo-Pujol
YR 2020
UL http://medrxiv.org/content/early/2020/11/19/2020.11.18.20233874.abstract
AB One of the entry routes of SARS-CoV-2 is the nasal epithelium. Although mounting evidence suggests the presence of olfactory dysfunction, and even anosmia, in patients with COVID-19, it is not clear whether these patients also suffer from other “nasal” symptoms that may influence their olfaction. A group of 35 patients with COVID-19 (and a control group matched in gender and age) were surveyed about the presence of a variety of nasal symptoms that may be associated to drastic perturbations experienced in the nasal cavity (e.g., “excessive dryness” and/or a continual sensation of having had a “nasal douche”). We used a cross-sectional, retrospective survey, targeted at the general population by means of non-quoted, non-random, snowball sampling. Symptoms were assessed with absence/presence responses. The possible association between two continuously distributed latent variables from categorical variables was estimated by means of polychoric correlations. More than 68% of the patients reported at least one “nasal” symptom. The clinical group also experienced “a strange sensation in the nose” and having excessive nasal dryness significantly more often than the control group. Fifty-two percent of the patients (but only 3% of the control group) reported a constant sensation of having had a strong nasal douche. Nasal symptoms predominantly co-occurred with anosmia/hyposmia, and ageusia/hypogeusia, appeared principally before or during the other symptoms of COVID-19, and lasted for twelve days, in average. The presence of these nasal symptoms, and their early occurrence, could potentially facilitate early diagnosis of COVID-19 and initial social distancing efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received to carry out this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been approved by the University of Barcelona's Bioethics Commission (CBUB) Code: IRB00003099All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available in the following repository: Open Science Framework https://osf.io/rwpjb/